Viewing Study NCT04379128


Ignite Creation Date: 2025-12-26 @ 11:10 AM
Ignite Modification Date: 2025-12-31 @ 3:26 PM
Study NCT ID: NCT04379128
Status: UNKNOWN
Last Update Posted: 2020-05-07
First Post: 2020-04-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Attentional Impairment in People With Epilepsy
Sponsor: Central Hospital, Nancy, France
Organization:

Study Overview

Official Title: Attentional Impairment in People With Epilepsy
Status: UNKNOWN
Status Verified Date: 2020-04
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ETAPE
Brief Summary: Epilepsy is one of the most common chronic neurological conditions.It leads to cognitive impairment in 20-50% of patients with a structural form.

In comparison with seizures, these cognitive disorders are a major additional factor in occupational, social and family disability. They are particularly frequent (50%) in temporal epilepsies and preferably concern memory and language skills.

The cognitive consequences of epilepsy are therefore well described in the following areas: episodic memory, language, executive functions.

Concerning attentional abilities, a recent review has highlighted the lack of work in this specific field in order to properly measure the prevalence and nature of attentional disorders in epileptic patients. Indeed, attentional abilities are often mentioned in studies, but attention is a complex domain defined by four modalities: alertness, selective attention, divided attention and sustained attention. No study systematically assesses all of these modalities.

The objective of this study is to evaluate the prevalence and nature of attentional disorders in epileptic patients compared to control subjects.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: